Viiv Healthcare, Medicines Patent Pool infectious news
ViiV granted the Medicines Patent Pool licenses to develop, manufacture and supply HIV drug Tivicay dolutegravir. Specifically, ViiV granted a royalty-free license in all least-developed, low-income and sub-Saharan African countries; a tiered royalty license for middle-income countries, including India, where a percentage of the sale price is paid based on the gross domestic product of the specific country; and a royalty-free license for pediatric formulations of dolutegravir in 121 countries where 99% of children with HIV live.
Tivicay, an HIV integrase inhibitor, is approved in the EU, U.S. and Japan to treat HIV infection in combination with other HIV drugs in patients at least 12 years old. The pediatric license includes a commitment for future lower dose tablets and age-appropriate formulations developed by ViiV for younger children if and when approved by a major regulatory authority. ...